Skip to main content
Potential first-in-class, targeted therapy for myasthenia gravis
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Potential first-in-class, targeted therapy for myasthenia gravis
User login
Username
Password
Reset your password
Concept
Lead
score
Myasthenia Gravis
1
1
Immunoglobulin G (IgG)
0
0.63
Biologic Therapy
0
0.53
Muscular Atrophy
0
0.51
Quality of Life
0
0.39
Receptors
0
0.39
Targeted Cancer Therapy
0
0.39
Refractory
0
0.29
Patient Safety
0
0.26
Skeletal Myoblasts
0
0.21
Food and Drug Administration (FDA)
0
0.2
Muscle
0
0.2
Otolaryngology
0
0.19
Upper Respiratory Tract Infection
0
0.14
Depression
0
0.13
Diarrhea
0
0.13
Headache
0
0.13
Muscular Dystrophy
0
0.13
Urinary Tract Infection
0
0.13
Adenocarcinoma
0
0.1
Adverse Effects
0
0.1
Autoimmune Disease
0
0.1
Blood
0
0.1
Europe
0
0.1
Immunoglobulin A (IgA)
0
0.1
Match
0
0.1
Nausea
0
0.1
Neuromuscular Diseases
0
0.1
Prescription Drugs
0
0.1
Respiratory Tract
0
0.1
Thrombocytosis
0
0.1
Weakness
0
0.1
Specialty
Lead
score
Pharmacist
1
0.7
Family Medicine/Primary Care
0
0.7
Internal Medicine
0
0.88
Neurology & Neurosurgery
0
1
Hematology-Oncology
0
0.66